TESTA, ANTONELLA FEDERICA

TESTA, ANTONELLA FEDERICA  

Dipartimento Sostenibilità dei Sistemi Produttivi e Territoriali (SSPT)  

Mostra records
Risultati 1 - 10 di 10 (tempo di esecuzione: 0.004 secondi).
Titolo Data di pubblicazione Autore(i) File
'BioQuaRT' project: Design of a novel In Situ protocol for the simultaneous visualisation of chromosomal aberrations and micronuclei after irradiation at microbeam facilities 1-gen-2015 Testa, A.; Pinto, M.; Patrono, C.
Dicentric Chromosome Assay (DCA) and Cytokinesis-Block Micronucleus (CBMN) Assay in the Field of Biological Dosimetry 1-gen-2019 Testa, A.; Palma, V.; Patrono, C.
Epidemiological, clinical, and molecular study of a cohort of Italian Parkinson disease patients: Association with glutathione-s-transferase and DNA repair gene polymorphisms 1-gen-2013 Poggioli, T.; Palma, V.; Testa, A.
Eurados review of retrospective dosimetry techniques for internal exposures to ionising radiation and their applications 1-gen-2020 Giussani, A.; Lopez, M. A.; Romm, H.; Testa, A.; Ainsbury, E. A.; Degteva, M.; Della Monaca, S.; Etherington, G.; Fattibene, P.; Guclu, I.; Jaworska, A.; Lloyd, D. C.; Malatova, I.; Mccomish, S.; Melo, D.; Osko, J.; Rojo, A.; Roch-Lefevre, S.; Roy, L.; Shishkina, E.; Sotnik, N.; Tolmachev, S. Y.; Wieser, A.; Woda, C.; Youngman, M.
THE EURADOS WORK TOWARDS A REVIEW ON RETROSPECTIVE DOSIMETRY AFTER INCORPORATION OF RADIONUCLIDES 1-gen-2019 Giussani, A.; Lopez, M. A.; Testa, A.
Evaluation of Levodopa and Carbidopa Antioxidant Activity in Normal Human Lymphocytes In Vitro: Implication for Oxidative Stress in Parkinsonメs Disease 1-gen-2014 Testa, A.
A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy 1-gen-2018 Testa, A.
A NOVEL BIOLOGICAL DOSIMETRY ASSAY AS A POTENTIAL TOOL FOR TRIAGE DOSE ASSESSMENT IN CASE OF LARGE-SCALE RADIOLOGICAL EMERGENCY 1-gen-2019 Testa, A.; Palma, V.; Patrono, C.
Resveratrol affects DNA damage induced by ionizing radiation in human lymphocytes in vitro 1-gen-2016 Testa, A.; Palma, V.
The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study 1-gen-2021 Sciuto, R.; Rea, S.; Ungania, S.; Testa, A.; Dini, V.; Tabocchini, M. A.; Patrono, C.; Soriani, A.; Palma, V.; Marconi, R.; Strigari, L.